Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Chief Business Officer | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rani Therapeutics Holdings, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2036-06-02 | Direct | 805,500 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 805,500 · Balance 805,500 F1: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from April 1, 2026, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from April 1, 2026, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 22:20 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 805,500 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001979211-26-000003 · ownership.xml · derivative · entry 1 McKinley Kate · CIK 0001979211 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 805,500 Underlying: Class A Common Stock · 805,500 shares Expires 2036-06-02 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from April 1, 2026, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through each such vesting date. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:12 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001415889-25-021027 · form4-08052025_080849.xml · derivative · entry 1 McKinley Kate · CIK 0001979211 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Class A Common Stock · 120,000 shares Expires 2035-07-31 Read SEC document |
| May 23, 2025 Filed May 23, 2025 22:20 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-25-077200 · ownership.xml · derivative · entry 1 McKinley Kate · CIK 0001979211 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,000 Underlying: Class A Common Stock · 325,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from May 23, 2025. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 23:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 17,960 | $1.67 | $29,993.20 |
DisclosureSEC source: 0000950170-24-136787 · ownership.xml · nonDerivative · entry 1 McKinley Kate · CIK 0001979211 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,960 Read SEC document |
| March 21, 2024 Filed Mar 23, 2024 01:25 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 323,500 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000950170-24-035576 · ownership.xml · derivative · entry 1 McKinley Kate · CIK 0001979211 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,500 Underlying: Class A Common Stock · 323,500 shares Expires 2034-03-20 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 21, 2024. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071475 · ownership.xml · derivative · entry 2 McKinley Kate · CIK 0001979211 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2033-05-21 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on May 22, 2024; and 1/48th of the shares subject to the option vest monthly over the remaining three years. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $4.13 | Not disclosed |
DisclosureSEC source: 0000950170-23-071475 · ownership.xml · derivative · entry 1 McKinley Kate · CIK 0001979211 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 250,000 shares Expires 2033-05-21 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on May 22, 2024; and 1/48th of the shares subject to the option vest monthly over the remaining three years. Read SEC document |
| May 22, 2023 Filed Aug 8, 2023 20:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0000899243-23-017839 · doc4.xml · derivative · entry 1 McKinley Kate · CIK 0001979211 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2033-05-21 F1 · derivative.exercise_date: The shares subject to the option vest 25% on May 22, 2024 and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.